Blog Posts

The pharmacy spend is real. The headlines are loud. And the pressure on self-funded plan sponsors to act on GLP-1 costs is growing louder every renewal cycle.

But the instinct to restrict or exclude these medications outright may be the most expensive decision a self-funded employer can make. The better question: how to cover GLP-1s in a way that actually works for the plan and for the people the plan is supposed to serve.

The Numbers Behind the Anxiety

GLP-1 receptor agonists (the class of medications that includes semaglutide and tirzepatide) carry a significant per-member price tag. According to Akerman, annual per-participant costs frequently exceed $10,000. As prescribing rates climb, plan sponsors are watching their pharmacy spend shift in ways that feel difficult to manage.

But pharmacy spend is only part of the picture. Members managing obesity, type 2 diabetes, and related cardiovascular conditions aren’t just generating drug claims. They’re generating inpatient admissions, emergency visits, specialist referrals, and downstream complications including cardiac, kidney, and liver failure, and even cancer. These costs can dwarf the investment in preventive therapy. When GLP-1 treatment is appropriate and working, it tends to reduce those downstream claims meaningfully. When it isn’t (because a member isn’t a clinical fit, isn’t adhering, or isn’t working with a clinician), the pharmacy spend delivers little, if anything, in return.

The challenge for most plan sponsors is that their current plan design doesn’t distinguish between those two scenarios. A blanket exclusion doesn’t solve the problem, and neither does unrestricted coverage. A smarter strategy does.

What “Smarter” Actually Means

Self-funding exists precisely so employers can design plans around their specific workforce, not a one-size-fits-all product built for someone else’s population. GLP-1 management is one of the clearest opportunities to put that flexibility to work.

A thoughtful approach typically starts with a few foundational elements.

Clinical criteria grounded in evidence. Coverage tied to documented clinical need (BMI thresholds, clinical labs, relevant diagnoses, prior authorization requirements, and documented clinical education and lifestyle modification support) serves a real purpose: it applies the same framework used to determine clinical appropriateness and protects members from being prescribed a high-cost medication that isn’t right for them. These medications work best when paired with thoughtful medical education, coaching, nutritional support, hydration, strength-building activity, and close attention to tolerability. The goal is healthier metabolism, preserved muscle, and sustainable outcomes, not weight loss alone.

Adherence and outcomes monitoring. GLP-1 efficacy is highly dependent on sustained use and appropriate clinical oversight. Plans that track whether members are continuing therapy, working with a care team, and achieving measurable health outcomes are far better positioned to evaluate the real return on their pharmacy spend. Integrated clinical resources, including care navigation and medical management programs, can play a meaningful role here, keeping members engaged and helping plan sponsors understand whether the investment is delivering results.

Whole-person program design. Medication alone rarely produces lasting outcomes. Programs that pair GLP-1 access with clinical nutritional support, behavioral health resources, and physician oversight address the full scope of what makes these interventions effective and provide a more defensible framework for coverage decisions when plan sponsors need to explain their approach to employees and stakeholders.

Transparent pharmacy benefit management. For high-cost drug classes, the structure of the pharmacy benefit matters as much as the coverage decision itself. Self-funded plans have leverage on pricing, rebates, and formulary design that fully-insured arrangements simply don’t. That leverage only translates to savings when the PBM relationship is built on genuine transparency and pass-through pricing, not arrangements that obscure where the dollars are going.

The Data Advantage

One of the most significant advantages self-funded employers hold in navigating GLP-1 costs is access to their own claims data. They can see which members are using these medications, what conditions those members are managing, what the downstream claims picture looks like, and whether their current approach is working. That level of insight isn’t available in a fully-insured model.

Data only creates value when someone is analyzing it and translating it into action. An independent TPA (one without carrier ownership or financial incentives tied to coverage decisions) is the right partner for that work. The goal is straightforward: help plan sponsors understand their own population and design a GLP-1 strategy that reflects it.

Don’t Overlook the Member Experience

Coverage decisions about GLP-1s affect real people managing serious health conditions. Members who have struggled with limited options are paying close attention to how their plan responds, and plan communication matters as much as plan design.

Thoughtful coverage design accounts for how decisions are communicated and how members are supported in navigating them. Both have a real impact on satisfaction, engagement, and downstream health outcomes. Member advocacy resources that help employees understand their coverage, explore clinically appropriate alternatives, or work through prior authorization processes can make a meaningful difference at the individual level and reduce the administrative friction that often drives dissatisfaction on both sides.

The Bottom Line

GLP-1 medications aren’t going away. The pipeline is expanding, clinical applications continue to grow, and employee expectations around coverage are shifting alongside them. Plan sponsors who restrict access reactively, without a clinical or data-driven framework, will find themselves managing both the financial and human fallout.

Self-funded employers have always had the tools to do this differently. The question is whether they’re using them, and whether they have a TPA partner committed to helping them build a strategy that works for their plan, their population, and their long-term goals.